Cingulate Inc CING

$5.19 -0.06 (-1.14%)

Valuation

Market cap
76,345,000
Revenue TTM
$0
Net income TTM
$-22,450,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
38,800
Avg volume
116,094
Day's range
$5.09 – $5.24
Shares out
14,542,000
Stochastic %K
66%
Beta
-0.88
Analysts
Strong Sell
Price target
$21.20

Price

Company profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-210...

Show more

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Industry
Biotechnology
Sector
Healthcare
Phone
913 942 2300
Website
https://www.cingulate.com
Address
1901 West 47th Place, Kansas City, United States

Latest news